MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.630
-0.040
-2.40%
Opening 09:32 04/10 EDT
OPEN
1.630
PREV CLOSE
1.670
HIGH
1.640
LOW
1.630
VOLUME
13.87K
TURNOVER
--
52 WEEK HIGH
4.555
52 WEEK LOW
1.480
MARKET CAP
111.43M
P/E (TTM)
-2.3751
1D
5D
1M
3M
1Y
5Y
1D
Cardiff Oncology appoints Mani Mohindru as CEO
Seeking Alpha · 19h ago
Cardiff Oncology appoints new CEO, CFO and COO
TipRanks · 19h ago
Cardiff Oncology Names Interim CEO to Role on Permanent Basis; Appoints CFO
Dow Jones · 19h ago
Cardiff Oncology Appoints Mani Mohindru As President And Chief Executive Officer; Josh Muntner Appointed As CFO
Benzinga · 19h ago
*Cardiff Oncology Names Ajay Aggarwal as Oper Chief >CRDF
Dow Jones · 19h ago
*Cardiff Oncology Appoints Josh Muntner as Chief Fincl Officer >CRDF
Dow Jones · 19h ago
*Cardiff Oncology: Board Member and Interim CEO Mani Mohindru, PhD, Named Pres and CEO >CRDF
Dow Jones · 19h ago
Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO
Reuters · 19h ago
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.